Structure Therapeutics News

Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $65

Moomoo NewsSep 23 08:33 ET

Structure Therapeutics Analyst Ratings

BenzingaSep 23 08:08 ET

Cantor Fitzgerald Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)

TipRanksSep 23 07:59 ET

Morgan Stanley Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $118

Moomoo NewsSep 23 05:33 ET

Buy Rating for Structure Therapeutics: GSBR-1290's Market Potential in Diabesity

TipRanksSep 23 04:47 ET

Structure Therapeutics Analyst Ratings

BenzingaSep 16 11:50 ET

JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $86

Moomoo NewsSep 10 13:32 ET

Buy Rating on Structure Therapeutics: Promising GSBR-1290 Clinical Developments and Competitive Market Positioning

TipRanksSep 10 12:38 ET

Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79

Moomoo NewsSep 10 08:31 ET

Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93

Moomoo NewsSep 10 07:33 ET

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy From Piper Sandler

TipRanksSep 10 06:41 ET

Structure Therapeutics Analyst Ratings

BenzingaAug 19 12:20 ET

Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $65

Moomoo NewsAug 15 08:31 ET

Structure Therapeutics Analyst Ratings

BenzingaAug 15 08:22 ET

Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target

BenzingaAug 15 08:22 ET

Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR) and AbSci (ABSI)

TipRanksAug 15 08:03 ET

Buy Rating Affirmed for Structure Therapeutics on Strong Pipeline and Undervalued Patent Portfolio

TipRanksAug 13 09:59 ET

Don't Forget This Startup's Weight-Loss Pill, Analyst Says -- Barrons.com

Barron'sAug 12 16:09 ET

Structure Therapeutics Analyst Ratings

BenzingaAug 9 14:47 ET

Leerink Partners Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $136

Moomoo NewsAug 1 02:32 ET